Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate


Treatment with α1-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15 mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4 ml from baseline in placebo patients but decreased by −0.25 ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months’ treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others


  1. Algaba F . Pathophysiology of benign prostatic hyperplasia. Eur Urol 1994; 25 (suppl 1): 3–5.

    Article  Google Scholar 

  2. Medina JJ, Parra RO, Moore RG . Benign prostatic hyperplasia (the aging prostate). Med Clin North Am 1999; 83: 1213–1229.

    Article  CAS  Google Scholar 

  3. Akduman B, Crawford ED . Terazosin, doxazosin, and prazosin: current clinical experience. Urology 2001; 58 (suppl 6A): 49–54.

    Article  CAS  Google Scholar 

  4. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N . α1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999; 161: 2002–2008.

    Article  CAS  Google Scholar 

  5. Kyprianou N, Chon J, Benning CM . Effects of alpha1-adrenoceptor (α1-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl 2000; 9: 42–46.

    Article  CAS  Google Scholar 

  6. Roehrborn CG, for the ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953–959.

    Article  CAS  Google Scholar 

  7. Terris MK, Stamey TA . Determination of prostate volume by transrectal ultrasound. J Urol 1991; 145: 984–987.

    Article  CAS  Google Scholar 

  8. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC . Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998; 159: 1810–1815.

    Article  CAS  Google Scholar 

  9. McKeage K, Plosker GL . Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633–653.

    Article  CAS  Google Scholar 

  10. Ahtoy P, Chrétien P, Dupain T, Rauch C, Rouchouse A, Delfolie A . Alfuzosin, an α1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. Int J Clin Pharmacol Ther 2002; 40: 289–294.

    Article  CAS  Google Scholar 

  11. Fulton B, Wagstaff AJ, Sorkin EM . Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295–320.

    Article  CAS  Google Scholar 

  12. Taguchi K, Schäfers RF, Michel MC . Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol 1998; 45: 49–55.

    Article  CAS  Google Scholar 

  13. Kyprianou N, Benning CM . Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60: 4550–4555.

    PubMed  CAS  Google Scholar 

Download references


The ALFUS study was sponsored by Sanofi-Synthelabo. Dr Roehrborn was funded investigator in the ALFUS trial.

Author information

Authors and Affiliations


Corresponding author

Correspondence to C G Roehrborn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roehrborn, C. Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9, 121–125 (2006).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links